
    
      This is a Phase I, open-label, parallel trial to evaluate Pharmacokinetics, Pharmacodynamics
      and Safety of Isosorbide Mononitrate gel for usage in participants with anal fissure and
      healthy volunteers.

      Investigational product will be randomly assigned as follows:

        -  healthy volunteers will receive 2g (2.0%) of investigational product at a single dose,
           and will undergo a washout period of 7 days; subsequently, they will receive 2g of
           investigational product once daily, for 7 consecutive days;

        -  participants with anal fissure will receive 2g of investigational product, either at
           0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days;
           subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or
           2.0%, once daily, for 7 consecutive days.
    
  